ALT Live signals | Maximize Profits with Getagraph.com

SELL 20932 min ago

@ $9.09

Issued: 5 Apr 2024 @ 16:00

Return: -23.98%

Previous signal: Apr 4 - 14:18

Previous signal: Buy

Return: -0.66 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	3.59M
Average Volume	4.82M
Market Cap	489.89M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-0.360 ) 2024-05-09
Last Dividend	$873.01 ( 2017-01-20 )
Next Dividend	$0 ( N/A )
P/E	-4.16
ATR14	$0.0210 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-02	Roberts M Scot	Buy	7 775	Common Stock, par value $0.0001
2024-02-02	Roberts M Scot	Sell	2 330	Common Stock, par value $0.0001
2024-02-01	Roberts M Scot	Buy	6 166	Common Stock, par value $0.0001
2024-02-01	Roberts M Scot	Sell	1 801	Common Stock, par value $0.0001
2024-02-02	Roberts M Scot	Sell	7 775	Restricted Stock Units

INSIDER POWER
81.82
Last 99 transactions
Buy: 2 849 671 \| Sell: 279 919

Volume Correlation

Long: 0.39 (neutral)

Short: 0.83 (strong)

Signal:(62.208) Same movement expected

Altimmune Inc Correlation

10 Most Positive Correlations
EBET	0.973
APEI	0.968
STRM	0.966
SY	0.964
ENTA	0.963
IMBI	0.963
CASA	0.958
SISI	0.958
CAMP	0.957
NSTG	0.957

10 Most Negative Correlations
LDHA	-0.979
JUGG	-0.979
ADAL	-0.978
CRZN	-0.977
HORI	-0.976
AHRN	-0.974
AGGR	-0.974
TBSA	-0.974
HCNE	-0.973
LEGA	-0.973

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Altimmune Inc Correlation - Currency/Commodity

-0.94
( very strong negative )

0.00
( neutral )

-0.93
( very strong negative )

-0.45
( neutral )

0.70
( moderate )

Altimmune Inc Financials

Annual	2023
Revenue:	$426 000
Gross Profit:	$-51 000.00 (-11.97 %)
EPS:	$-1.660

Q4	2023
Revenue:	$37 000.00
Gross Profit:	$-1.85M (-5 008.11 %)
EPS:	$-0.540

Q3	2023
Revenue:	$362 000
Gross Profit:	$-18.03M (-4 979.56 %)
EPS:	$-0.390

Q2	2023
Revenue:	$6 000.00
Gross Profit:	$-13.25M (-220 783.33 %)
EPS:	$-0.320

Financial Reports:

No articles found.

Altimmune Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Altimmune Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$873.01	2017-01-20
Last Dividend	$873.01	2017-01-20
Next Dividend	$0	N/A
Payout Date	2017-02-03
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$873.01	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-20)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2017	$873.01	655.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-203.67	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.412	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.510	1.500	-6.78	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	17.25	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	16.69	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	11.13	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00319	-1.500	9.95	-10.00	[0 - 0.6]
interestCoverageTTM	3 630.87	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.297	2.00	-0.432	-0.865	[0 - 30]
freeCashFlowPerShareTTM	-1.298	2.00	-0.649	-1.298	[0 - 20]
debtEquityRatioTTM	0.00346	-1.500	9.99	-10.00	[0 - 2.5]
grossProfitMarginTTM	-76.88	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-196.03	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-112.98	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00202	0.800	-3.32	-2.66	[0.5 - 2]
Total Score				-0.982

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-5.40	1.000	-0.646	0	[1 - 100]
returnOnEquityTTM	-0.510	2.50	-4.36	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.298	2.00	-0.433	-1.298	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.297	2.00	-0.432	-0.865	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0783	1.500	-3.86	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-177.96	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.82

Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.